 | Up a level |
Waldschmidt, D., Merle, P., Granito, A., Huang, Y-H, Bodoky, G., Yokosuka, O., Rosmorduc, O., Breder, V. V., Gerolami, R., Masi, G., Ross, P. J., Qin, S., Song, T., Bronowicki, J-P, Ollivier-Hourmand, I, Kudo, M., Xu, L., Baumhauer, A., Meinhardt, G., Han, G. and Bruix, J. (2018). Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib. Oncol. Res. Treat., 41. S. 281 - 282. BASEL: KARGER. ISSN 2296-5262
Waldschmidt, D., Teufel, M., Koechert, K., Meinhardt, G. and Bruix, J. (2018). Efficacy of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial according to alpha-fetoprotein (AFP) and c-Met levels as predictors of poor prognosis. Oncol. Res. Treat., 41. S. 281 - 283. BASEL: KARGER. ISSN 2296-5262